Xeris insider plans sale of 42,500 shares via Morgan Stanley — Form 144

Rhea-AI Filing Summary

Xeris Biopharma Holdings, Inc. (XERS) submitted a Form 144 reporting a proposed sale of 42,500 common shares through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $309,225.75. The shares were acquired on 06/05/2024 by restricted stock vesting under a registered plan and the filing lists an approximate sale date of 08/12/2025.

The filing shows 161,480,367 shares outstanding, so the proposed sale is a very small portion of the company (approximately 0.026% of outstanding shares). The notice states there were no securities sold by the seller in the past three months and includes the seller's representation that they are not aware of any undisclosed material adverse information about the issuer. No earnings, financing, or management changes are disclosed in this filing.

Positive

• Planned sale quantified: 42,500 common shares with an aggregate market value of $309,225.75
• Acquisition method disclosed: shares were acquired by restricted stock vesting under a registered plan on 06/05/2024
• Compliance disclosure present: sale to be executed through Morgan Stanley Smith Barney LLC and seller attests to no undisclosed material adverse information

Negative

• None.

Insights

Securities Analyst

TL;DR: Small, routine Form 144 filing for an insider sale; unlikely to move markets.

The filing documents a proposed sale of 42,500 common shares valued at $309,225.75 via Morgan Stanley Smith Barney LLC, representing roughly 0.026% of 161,480,367 outstanding shares. That scale suggests the transaction is immaterial to company capitalization and unlikely to signal a change in corporate fundamentals. The shares were issued via restricted stock vesting on 06/05/2024 and no other sales in the past three months are reported, indicating this is an isolated planned disposition rather than part of a larger, ongoing sell-down.

Corporate Governance Expert

TL;DR: Filing meets disclosure expectations; no governance red flags visible from this notice.

The Form 144 lists the broker, nature of acquisition (restricted stock vesting), and seller representation regarding material information, aligning with standard compliance for Rule 144 dispositions. There is no indication of undisclosed related-party transactions, unusual timing, or aggregated sales over the prior three months. Absent additional context or concurrent filings, this notice appears to be a routine compliance disclosure rather than a governance concern.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	42500	309225.75	161480367	08/12/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/05/2024	Restricted stock vesting under a registered plan	Issuer			42500	06/05/2024	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did Xeris Biopharma (XERS) report on Form 144?

The company reported a proposed sale of 42,500 common shares via Morgan Stanley Smith Barney LLC with an aggregate market value of $309,225.75.

When were the shares being sold by the XERS filer acquired?

The shares were acquired on 06/05/2024 through restricted stock vesting under a registered plan.

What is the expected sale date listed in the XERS Form 144?

The filing lists an approximate date of sale of 08/12/2025.

How large is the proposed sale relative to Xeris' outstanding shares?

The filing shows 161,480,367 shares outstanding, so the 42,500-share sale represents about 0.026% of outstanding shares.

Were there any securities sold by the filer in the past three months?

The Form 144 states "Nothing to Report" for securities sold during the past three months.